Bafna Pharmaceuticals Ltd Financial Statement
*All values are in Rs. Cr
| Particulars | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|
| Revenue | 41.35 | 33.79 | 41.91 |
| Operating Expense | 36.53 | 32.42 | 38.51 |
| Net Profit | 2.62 | -0.72 | 1.46 |
| Net Profit Margin | 6.34 | -2.13 | 3.48 |
| Earning Per Share | 1.11 | -0.31 | 0.62 |
| EBIDTA | 4.82 | 1.37 | 3.41 |
| Effective Tax Rate | TBA | TBA | TBA |
| Particulars | Sep 2024 |
|---|---|
| Revenue | 41.35 |
| Operating Expense | 36.53 |
| Net Profit | 2.62 |
| Net Profit Margin | 6.34 |
| Earning Per Share | 1.11 |
| EBIDTA | 4.82 |
| Effective Tax Rate | TBA |
Invest in Bafna Pharmaceuticals Ltd
₹0 Brokerage*
Open Demat Account
*By signing up you agree to our Terms and Conditions
*All values are in Rs. Cr
Standalone
Consolidated
| Particulars | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|
| Total Revenue Annual | 152.47 | 115.35 | 85.14 |
| Operating Expenses Annual | 141.35 | 99.63 | 73.18 |
| Operating Profit Annual | 14.63 | 18.99 | 11.50 |
| Interest Annual | 2.29 | 2.04 | 0.79 |
| Depreciation | 5.00 | 5.33 | 5.49 |
| Net Profit Annual | 7.35 | 11.34 | 5.22 |
| Tax Annual | TBA | 0.28 | TBA |
| Particulars | Mar 2024 |
|---|---|
| Total Revenue Annual | 152.47 |
| Operating Expenses Annual | 141.35 |
| Operating Profit Annual | 14.63 |
| Interest Annual | 2.29 |
| Depreciation | 5.00 |
| Net Profit Annual | 7.35 |
| Tax Annual | TBA |
*All values are in Rs. Cr
Standalone
Consolidated
| Particulars | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|
| Cash Flow at the Beginning | 7.81 | 0.17 | 1.80 |
| Cash Flow from Operations | 9.48 | 4.95 | 9.73 |
| Cash Flow from Investing | -15.05 | -7.49 | -6.54 |
| Cash Flow from Financing | -0.85 | 10.18 | -4.81 |
| Cash Flow at the End | 1.40 | 7.81 | 0.17 |
| Particulars | Mar 2024 |
|---|---|
| Cash Flow at the Beginning | 7.81 |
| Cash Flow from Operations | 9.48 |
| Cash Flow from Investing | -15.05 |
| Cash Flow from Financing | -0.85 |
| Cash Flow at the End | 1.40 |
*All values are in Rs. Cr
Standalone
Consolidated
| Particulars | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|
| PBDIT Margin (%) | 9.60 | 16.46 | 16.04 |
| PBIT Margin (%) | 6.32 | 11.84 | 9.60 |
| PBT Margin (%) | 3.56 | 6.03 | -2.54 |
| Net PROFIT Margin (%) | 4.82 | 9.83 | 6.13 |
| Return On Networth / Equity (%) | 5.74 | 8.86 | 5.77 |
| Return On Networth /Employed (%) | 6.29 | 9.36 | 5.77 |
| Return On Assets (%) | 7.18 | 13.27 | 7.17 |
| Total Debt / Equity (X) | 0.31 | 0.25 | 0.22 |
| Asset Turnover Ratio (%) | 1.49 | 1.35 | 1.17 |
| Particulars | Mar 2024 |
|---|---|
| PBDIT Margin (%) | 9.60 |
| PBIT Margin (%) | 6.32 |
| PBT Margin (%) | 3.56 |
| Net PROFIT Margin (%) | 4.82 |
| Return On Networth / Equity (%) | 5.74 |
| Return On Networth /Employed (%) | 6.29 |
| Return On Assets (%) | 7.18 |
| Total Debt / Equity (X) | 0.31 |
| Asset Turnover Ratio (%) | 1.49 |
*All values are in Rs. Cr
Standalone
Consolidated
| Particulars | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|
| Fixed Assets Annual | 41.98 | 41.73 | 38.85 |
| Total Current Assets Annual | 94.47 | 87.31 | 50.88 |
| Non Current Assets Annual | 53.21 | 42.27 | 39.26 |
| Total Shareholders Funds Annual | 80.84 | 73.45 | 61.96 |
| Total Assets Annual | 147.68 | 129.58 | 90.14 |
| Particulars | Mar 2024 |
|---|---|
| Fixed Assets Annual | 41.98 |
| Total Current Assets Annual | 94.47 |
| Non Current Assets Annual | 53.21 |
| Total Shareholders Funds Annual | 80.84 |
| Total Assets Annual | 147.68 |
EPS (INR)
Expected
0.00
Reported
-0.25
Surprise
0.00%
Jun 2019
EPS beaten by 0.00%
Sep 2018
EPS beaten by 0.00%
Jun 2018
EPS beaten by 0.00%
